The COVID-19 symptoms have been particularly associated with thrombosis in patients. Indeed, according to Talasaz et al. (2021), “microvascular and macrovascular thrombotic complications including arterial and especially venous thromboembolism (VTE) appear to be common clinical manifestations of coronavirus disease 2019” (p. 4). The prevalence of thrombosis as a characteristic of Coronavirus and its complications for patients with chronic conditions eligible for anticoagulation therapy-induced new approaches to emergency and remote anticoagulation use (Cope et al., 2021). The problems with the retrieval of data diagnosing for such comorbidities and dosage, which are being developed by scholars obstruct timely therapy administering.
There are significant challenges to using anticoagulants in COVID-19 patients. According to the American Society of Hematology (2021), the lack of sufficient information on the disease’s outcomes and the dosages of blood thinners are the difficulties experienced by healthcare workers. Moreover, the inability to administer proper treatment to all patients at risk of thrombosis is related to the diminished awareness of non-hospitalized patients about such a threat (Doganci & Yildirim, 2020). Comorbidities that are associated with the venous system might be a significant challenge when administering anticoagulant or blood-thinning medication to patients with COVID-19 due to the risk of complications (Doganci & Yildirim, 2020). Finally, the decision to administer anticoagulation is bound to the thrombosis/bleeding ratio analysis to eliminate harm (American Society of Hematology, 2021).
American Society of Hematology. (2021). COVID-19 and VTE/Anticoagulation: Frequently asked questions. Web.
Cope, R., Fischetti, B., Eladghm, N., Elaskandrany, M., & Karam, N. (2021). Outpatient management of chronic warfarin therapy at a pharmacist-run anticoagulation clinic during the COVID-19 pandemic. Journal of Thrombosis and Thrombolysis, 1-5. Web.
Doganci, S., & Yildirim, A. K. (2020). Problems related to anticoagulant usage during COVID-19 outbreak. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 8(4), 695-696.
Talasaz, A. H., Sadeghipour, P., Kakavand, H., Aghakouchakzadeh, M., Van Tassell, B. W., Kordzadeh-Kermani, E., Van Tassell, B. W., Gheymati, A., Ariannejad, H., Hosseini, S. H., Jamalkhani, S., Sholzberg, M., Monrea, M., Jimenez, D., Piazza, G., Parikh, S. A., Kirtane, A., J., Eikelboom, J. W., Connors, J. M.,… & Bikdeli, B. (2021). Antithrombotic therapy in COVID-19: systematic summary of ongoing or completed randomized trials. MedRxiv. Web.